Mineralys Therapeutics, Inc./$MLYS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Ticker
$MLYS
Sector
Primary listing
Employees
76
Headquarters
Website
MLYS Metrics
BasicAdvanced
$2.2bn
-
-$2.29
0.57
-
Price and volume
Market cap
$2.2bn
Beta
0.57
52-week high
$47.65
52-week low
$12.59
Average daily volume
1.3m
Financial strength
Current ratio
43.763
Quick ratio
43.448
Profitability
EBITDA (TTM)
-170.545
Management effectiveness
Return on assets (TTM)
-24.58%
Return on equity (TTM)
-36.91%
Valuation
Price to book
3.4
Price to tangible book (TTM)
3.4
Price to free cash flow (TTM)
-12.821
Free cash flow yield (TTM)
-7.80%
Free cash flow per share (TTM)
-2.105
Growth
Earnings per share change (TTM)
-37.60%
3-year earnings per share growth (CAGR)
-26.54%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mineralys Therapeutics, Inc. stock?
Mineralys Therapeutics, Inc. (MLYS) has a market cap of $2.2B as of April 28, 2026.
What is the P/E ratio for Mineralys Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Mineralys Therapeutics, Inc. (MLYS) stock is 0 as of April 28, 2026.
Does Mineralys Therapeutics, Inc. stock pay dividends?
No, Mineralys Therapeutics, Inc. (MLYS) stock does not pay dividends to its shareholders as of April 28, 2026.
When is the next Mineralys Therapeutics, Inc. dividend payment date?
Mineralys Therapeutics, Inc. (MLYS) stock does not pay dividends to its shareholders.
What is the beta indicator for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. (MLYS) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.